Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

National Defense January 2014 Cannon & Scott	Anti-Bribery Law Demands Vigilance November marked the one-year anniversary of the release of the resource guide to the Foreign Corrupt Practices Act, and should serve to remind all defense contractors of the critical importance of keeping their compliance program current and effective.
Pharmaceutical Executive May 1, 2006 Cook & Witten	Legal: The Kickback Effect Pharma tends not to treat relationships with foreign doctors as cautiously as it does those with US physicians. But watch out: Misconduct on the part of your international employees could get kicked back onto your plate.
National Defense July 2010 Anderson & Goodwin	Anti-Bribery Case in China a Wake-Up Call The recent Rio Tinto case in China is a powerful reminder why a vigilant and robust Foreign Corrupt Practices Act of 1977 (FCPA) corporate compliance program is important.
Pharmaceutical Executive June 1, 2007 Cook & Leiken	Legal: Foreign Policy Drug companies doing business abroad face a special risk of running afoul of stepped-up enforcement of anticorruption laws.
National Defense September 2015 Kopp & Bhatia	U.S. Cracking Down on Defense Industry Corruption Overseas The race for international sales during the past few years has been followed by a wave of government investigations into defense companies for both major and relatively minor violations of the Foreign Corrupt Practices Act.
National Defense July 2009 Latour & Maki	Companies Must Resist Temptations to Cut Corners The defense industry must counter any temptation to cut corners that could result in violations of the Foreign Corrupt Practices Act (FCPA).
National Defense September 2005 Shaheen & Geren	Penalties Get Tougher For FCPA Violations The government is cracking down on bribes by government contractors to foreign officials.
Pharmaceutical Executive October 1, 2005 Andy Bender	Orchestrating Compliance Product managers at pharmaceuticals are not always happy to see their compliance officers. That may be changing.
National Defense August 2010 Patrick & Renzulli	Defense Contractors Increasingly Targeted in Corruption Investigations Companies and individuals are facing dramatically higher penalties and costs for failing to comply with anti-bribery laws around the world, and especially in the United States.
Bio-IT World January 12, 2004	PDMA Compliance in 12 Steps Prescription Drug Marketing Act violations can cost millions. To save that money, follow this program.
Pharmaceutical Executive January 1, 2012	Compliance: Getting Those Ducks in a Row Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
CFO February 1, 2012 Sarah Johnson	Don't Trust, Verify With antibribery actions on the rise, companies should monitor their business partners more closely than ever.
Inc. August 2007 Alison Stein Wellner	No Free Pass Anti-bribery law is now being aggressively enforced.
CFO January 1, 2005 David M. Katz	The Bribery Gap While foreign rivals may make payoffs routinely, U.S. firms face new pressure to root out abuses.
CFO January 1, 2008 Kate O'Sullivan	Foreign Intelligence CFOs need to be smart about overseas operations -- or risk paying a heavy price.
National Defense December 2010 O'Neill et al.	The Long Arm Of the U.K. Bribery Act For U.S. companies, particularly those active in foreign countries or engaged in high-profile markets such as the defense industry, maintaining ethical operations and avoiding corruption is essential.
National Defense November 2010 Marinelli & Latour	Vetting Partners: A Key Compliance Element Vetting vendors and other partners is a critical element of a comprehensive export compliance program.
IndustryWeek March 16, 2011	Schooled By Scandals Manufacturers burned by foreign bribery scandals provide valuable lessons for companies expanding their global presence.
National Defense February 2011 Pappalardo & Bombach	Justice Department Beefs Up Foreign Corruption Act Enforcement Enforcement of the Foreign Corrupt Practices Act gained momentum in 2010.
Pharmaceutical Executive September 1, 2008 Herschman & Khorover	The New Code Effective January 1st, sales reps will have a new standard for dealing with doctors with a revised "Code on Interactions with Healthcare Professionals."
National Defense November 2015 Bradel & Ralph	Justice Memo Calls for Absolute Cooperation The Foreign Corrupt Practices Act is a statute aimed at eliminating corporate bribery of foreign government officials. A defense contractor doing work overseas must be familiar with its tenets.
Pharmaceutical Executive January 1, 2013 Ben Comer	Compliance in the C-Suite Compliance officers have risen into pharmaceutical management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Entrepreneur September 2004 Jane Easter Bahls	Illicit Affairs? If you do business overseas, be certain your "administrative fees" aren't really illegal bribes. And because complying with the many overlapping laws is tricky, hire a lawyer with experience in international business.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
National Defense November 2011 Piazza & Ayers	Regulators Flex Foreign Corrupt Practices Act Enforcement Muscles Continuing a trend that started late in the last decade, the Securities and Exchange Commission this year continues to raise the bar on the enforcement of the Foreign Corrupt Practices Act of 1977.
Pharmaceutical Executive March 1, 2009 Jill Wechsler	Through the Looking Glass Pharma relations with researchers are critical for developing new technology, and reformers will discourage inappropriate relationships by making any links to pharmaceutical marketing known to all.
Chemistry World June 5, 2009 Anna Lewcock	Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
CFO April 15, 2012 Sarah Johnson	Coverage for Uncovered Secrets New insurance products will compensate companies for the costs of internal investigations.
Pharmaceutical Executive August 1, 2014 Severin Wirz	Only Fools Rush In The importance of pre-acquisition due diligence.
BusinessWeek July 8, 2010 Dexter Roberts	The Higher Costs of Bribery in China The U.S. is policing the activities of big multinationals in China more aggressively, with China's own prosecutors sometimes following suit.
Pharmaceutical Executive September 1, 2012 Thomas Baker	The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support.
Investment Advisor August 2006 Thomas D. Giachett	Expert's Corner: A Process, Not a Destination With the advent of SEC Rule 206(4) 7, which requires SEC-registered investment advisors to implement and maintain policies and procedures appropriate for their investment advisory business, it is more critical than ever for all RIAs to recognize that compliance is an ongoing process.
Pharmaceutical Executive December 1, 2010 William Looney	Is Euroland Following the US Disclosure Lead? Cegedim Relationship Management survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spending.
Pharmaceutical Executive September 1, 2005 Wilkenfeld & Braun-Davis	50 5 2005 Five things pharmaceutical companies can do to prepare for compliance in all 50 states.
National Defense January 2016 Thomas B. McVey	Executives: Be Wary of Export Regulations One of the important legal requirements facing defense contractors is compliance with International Traffic in Arms Regulations and export controls.
CFO September 1, 2008 Kate O'Sullivan	Gunning for Global Graft The Department of Justice and the SEC turn up the heat on briberies of foreign officials.
Pharmaceutical Executive December 1, 2005 Patrick Clinton	PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products.
CFO April 1, 2006 John Goff	Coming Distractions As big a concern as E-waste is, it is still only a small bite in the larger risk grid confronting business managers these days. Here are eight risks managers need to focus on. Green Laws: No Hazmats Beyond This Point... Terrorism Insurance: Duck and Cover... etc.
Bio-IT World January 12, 2004 Steve Lefar	Systematize Your Regulatory Info! Want better protection against regulation breaches? Build a system that engenders 'grassroots' compliance.
National Defense July 2011 Lisa Navarro	U.K. Issues Guidance For Bribery Act On July 1, the United Kingdom's Bribery Act 2010 finally comes into force. U.S. firms with U.K.-based activities appear to be covered by the act, as are firms that have significant sales in or from the United Kingdom.
The Motley Fool July 31, 2009 Brian Orelli	Can Emerging Markets Save Pharma? Probably not until after they emerge.
Bio-IT World April 15, 2003 Barbara Depompa Reimers	Easing the Pain of Part 11 Costs for complying with FDA electronic records regulations will cost millions of dollars per company by 2006. Risk-based processes can lighten the load.
Pharmaceutical Executive January 1, 2007 Glass & Poli	Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges.
The Motley Fool November 11, 2004 Rich Smith	SEC Targets Lucent Ex-Execs Investigation into alleged Saudi bribery by its Chinese subsidiary moves ahead. Lucent's stock has dropped 15% in value.
Financial Planning September 1, 2006 Jane Worthington	Accounting for Compliance Instead of viewing compliance as a necessary evil, financial advisors should see it as a cost of doing business and learn how to quantify that cost.
Chemistry World October 7, 2015 Phillip Broadwith	Bristol-Myers-Squibb fined for alleged Chinese bribes The US Securities and Exchange Commission has fined New York based pharmaceutical company Bristol-Myers Squibb over $14 million over alleged bribes made to Chinese state owned hospitals.
Pharmaceutical Executive September 1, 2010	Maintaining a Culture of Compliance In order to sustain compliance it must become a core component of every company's training, sales processes, and incentive programs.